Form 4: Corbus Pharmaceuticals Director, Yong Ben, Receives Stock Option Award

Director Yong Ben received a stock option award for 2,783 shares of Corbus Pharmaceuticals common stock on May 16, 2024.

Summary

• Yong Ben, a director of Corbus Pharmaceuticals Holdings, Inc., was granted a stock option to purchase 2,783 shares of common stock on May 16, 2024.
• The exercise price of the option is $45.92 per share.
• The options vest 100% on the one-year anniversary of the grant date and expire on May 16, 2034.
• The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan.

Sentiment

Score: 6

Explanation: The document reflects a routine compensation practice. It's neutral in sentiment as it simply reports the granting of stock options.

Positives

• The granting of stock options to directors aligns their interests with those of shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant and vesting schedule are typical for director compensation, aligning with industry practices to incentivize long-term value creation.
• Comparable companies often use similar equity compensation plans to attract and retain qualified board members.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to make decisions that increase shareholder value.
• The grant has a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates